Our systematic review in BMC Psychiatry concluded that selective serotonin reuptake inhibitors ( SSRIs ) compared with placebo significantly increase the risk of serious adverse events ( SAEs ) in patients with major depression and the potential beneficial effects of SSRIs seem to be outweighed by the harms .
In their post-hoc analysis of our data , they reported that SSRIs only increase the risk of SAEs in elderly and seems safe for non-elderly patients .
Paroxetine in the treatment of depression: a comparison with imipramine and placebo.
Paroxetine is a selective serotonin reuptake inhibitor with significant antidepressant properties . This was a 6-week placebo- and imipramine-controlled study of 120 out patients with major depression .  Paroxetine was statistically significantly superior to placebo on almost all outcome measures . This was apparent as early as 1 week . Paroxetine was also significantly superior to imipramine on the Hamilton Rating Scale for Depression total score .  Paroxetine was generally better tolerated than imipramine . These results strongly support paroxetine 's effectiveness in the treatment of major depression and suggest that paroxetine will be a valuable addition to the options in treating depressive illness
Our systematic review in BMC Psychiatry concluded that selective serotonin reuptake inhibitors ( SSRIs ) compared with placebo significantly increase the risk of serious adverse events ( SAEs ) in patients with major depression and the potential beneficial effects of SSRIs seem to be outweighed by the harms .
In their post-hoc analysis of our data , they reported that SSRIs only increase the risk of SAEs in elderly and seems safe for non-elderly patients .